Aspire Biopharma Holdings Inc.(ASBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASBP Aspire Biopharma Holdings Inc.

Market Closed 02-27 16:00:00 EST

1.39

-0.06

-4.14%

盘后1.38

-0.01-0.72%

19:59 EST

High1.45	Low1.38	Vol57.10K
Open1.41	D1 Closing1.45	Amplitude4.83%
Mkt Cap6.98M	Tradable Cap4.26M	Total Shares5.02M
T/O80.58K	T/O Rate1.86%	Tradable Shares3.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASBP","market":"US","secType":"STK","nameCN":"Aspire Biopharma Holdings Inc.","latestPrice":1.39,"timestamp":1772226000000,"preClose":1.45,"halted":0,"volume":57096,"hourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.39,"latestTime":"19:59 EST","volume":10792,"amount":15165.8724,"timestamp":1772240379082,"change":-0.01,"changeRate":-0.007194,"amplitude":0.028777},"delay":0,"changeRate":-0.04137931034482763,"floatShares":3066100,"shares":5024142,"eps":-65.96,"marketStatus":"Market Closed","change":-0.06,"latestTime":"02-27 16:00:00 EST","open":1.41,"high":1.45,"low":1.38,"amount":80576.5073256,"amplitude":0.048276,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-65.96,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.45,"preHourTrading":{"tag":"盘前","latestPrice":1.41,"preClose":1.45,"latestTime":"09:29 EST","volume":552,"amount":766.4901432,"timestamp":1772202599510,"change":-0.04,"changeRate":-0.027586,"amplitude":0.040069},"postHourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.39,"latestTime":"19:59 EST","volume":10792,"amount":15165.8724,"timestamp":1772240379082,"change":-0.01,"changeRate":-0.007194,"amplitude":0.028777},"volumeRatio":0.310928},"requestUrl":"/m/hq/s/ASBP","defaultTab":"news","newsList":[{"id":"2614877030","title":"Aspire Biopharma Subsidiary Buzz Bomb Caffeine Company Posts Record Social Media Growth and Sales Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2614877030","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614877030?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:30","pubTimestamp":1772026233,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.’s wholly owned subsidiary, Buzz Bomb Caffeine Company, reported record social media growth and a surge in online revenue following its sponsorship of ultra-marathoner Ashley Paulson at the 2026 Jackpot Ultra Running Festival. Buzz Bomb said its content topped 400,000 views in 48 hours after Paulson set a women’s world record in the USATF 100-Mile Road Championship, and highlighted its 50mg caffeine stick-pack products offered in four flavors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLdKlbd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2612640262","title":"Aspire Biopharma Regains Nasdaq Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612640262","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612640262?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:00","pubTimestamp":1771592447,"startTime":"0","endTime":"0","summary":"Aspire Biopharma said Nasdaq has confirmed the company regained compliance with continued listing rules, including the $2.5 million minimum stockholders’ equity requirement and the $1.00 minimum bid price rule, allowing its shares to remain listed. Nasdaq also placed Aspire under a one-year “Panel Monitor” through Feb. 18, 2027, meaning any renewed equity deficiency would require a hearing before a Nasdaq panel rather than submission of a standard compliance plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL4nG6PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2612400084","title":"Aspire Biopharma Holdings Inc. Makes Investor Presentation Available","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400084","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400084?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:33","pubTimestamp":1771508032,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. published an investor presentation titled “Aspire Biopharma Investor Presentation February 2026,” available at I Accept.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on February 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL2yTnMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2612407701","title":"Aspire Subsidiary Buzz Bomb Caffeine Names ChicExecs PR Agency of Record","url":"https://stock-news.laohu8.com/highlight/detail?id=2612407701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612407701?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506038,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.’s wholly owned subsidiary, Buzz Bomb Caffeine Company, has named ChicExecs as its public relations agency of record. ChicExecs will lead BUZZ BOMB communications strategy, including media relations, events, strategic partnerships, and PR-led campaign planning, as the brand pursues expansion, product innovation, and a refreshed market presence.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL1Ctr4W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2612493620","title":"BRIEF-Aspire Biopharma Says Resale Of Up To 159.1 Mln Shares Of Common Stock Underlying Series A Convertible Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2612493620","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612493620?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:43","pubTimestamp":1771364593,"startTime":"0","endTime":"0","summary":"BRIEF-Aspire Biopharma Says Resale Of Up To 159.1 Mln Shares Of Common Stock Underlying Series A Convertible Preferred StockFeb 17  - Aspire Biopharma Holdings Inc ASBP.O:ASPIRE BIOPHARMA HOLDINGS INC: RESALE OF UP TO 159,090,906 SHARES OF COMMON STOCK UNDERLYING SERIES A CONVERTIBLE PREFERRED STOCKSource text: [ID:n0001493152-26-007123]Further company coverage: ASBP.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2612983214","title":"Aspire Biopharma Holdings Inc: Resale of up to 159,090,906 Shares of Common Stock Underlying Series a Convertible Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2612983214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612983214?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:19","pubTimestamp":1771363158,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2611152445","title":"Aspire Biopharma Appoints Phillip Balatsos to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152445","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152445?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:01","pubTimestamp":1770987678,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has appointed Phillip Balatsos to its Board of Directors, effective February 6, 2026. Balatsos, who brings experience from global financial institutions and board roles at other companies, will also serve on the Audit and Compensation Committees. This appointment follows the departures of Suren Ajjarapu and Donald G. Fell from the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL735jqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2610921054","title":"Aspire Biopharma files patent application for sublingual ondansetron formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610921054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610921054?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:38","pubTimestamp":1770903529,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced the filing of a provisional patent application with the United States Patent and Trademark Office. The a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-ondansetron-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-ondansetron-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2610371399","title":"Aspire Biopharma Raises $21 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2610371399","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610371399?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:51","pubTimestamp":1770814262,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  has announced a $21 million private placement through a securities purchase agreement with select institutional and accredited investors. The agreement, signed on February 6, 2026, involves the purchase and sale of up to 26,250 shares. This move is aimed at strengthening the company’s balance sheet, enhancing its capital position, and fortifying shareholder equity to meet Nasdaq requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc4cR6q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2609051291","title":"Aspire Biopharma Amends Bylaws to Designate Series A Preferred Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2609051291","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609051291?lang=en_us&edition=fundamental","pubTime":"2026-02-07 06:26","pubTimestamp":1770416779,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has amended its bylaws to designate 25,000 shares of Series A Convertible Preferred Stock, detailing terms such as conversion rights, limited voting rights, liquidation preferences, participation rights in future financings, and price protection provisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL59f970:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2609308887","title":"Buzz Bomb Caffeine Company Showcases Sublingual Supplement at Sports Nutrition Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2609308887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609308887?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:00","pubTimestamp":1770296453,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc.  operates through its wholly owned subsidiary, Buzz Bomb Caffeine Company. Buzz Bomb Caffeine Company markets BUZZ BOMB, a proprietary sublingual caffeine supplement designed for rapid absorption and convenience. The subsidiary recently launched a redesigned website and updated product branding, and is set to showcase its flagship product at The Sports & Active Nutrition Summit USA in San Diego.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL141NP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2608387983","title":"Aspire Biopharma Subsidiary Buzz Bomb Signs Distribution Agreement with Blue Shark Beverages","url":"https://stock-news.laohu8.com/highlight/detail?id=2608387983","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608387983?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123617,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc., through its wholly owned subsidiary Buzz Bomb Caffeine Company, has entered into a strategic brand management and distribution agreement with Blue Shark Beverages. The agreement, effective February 1, 2026, is intended to expand the retail distribution of BUZZ BOMB, a 50mg sublingual caffeine stick pack, in key Southern California markets. The product rollout will begin in Palm Springs and the Coachella Valley, with a phased expansion into the Los Angeles and San Diego metropolitan areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 03, 2026, and is solely responsible for the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLZn5LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2607024749","title":"Aspire Biopharma Holdings Announces Private Placement of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2607024749","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607024749?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:06","pubTimestamp":1769810792,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced an unregistered sale of equity securities through a private placement, as disclosed in a recent filing. Further details regarding the terms and size of the offering were referenced in Item 1.01 of the filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL7Gsf7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2607087678","title":"Aspire Biopharma Signs Development Agreement with Microsize for Sublingual Aspirin","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087678","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087678?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:00","pubTimestamp":1769691654,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced an agreement with Microsize, a contract development and manufacturing organization specializing in particle size engineering for the pharmaceutical industry. Under the agreement, Microsize will support the development of Aspire's sublingual aspirin product by providing expertise in micronization and solubility enhancement. This collaboration aims to optimize the drug product for an upcoming clinical trial and support the planned submission of a New Drug Application for Aspire's 162 mg sublingual aspirin for the emergency treatment of suspected acute myocardial infarction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL8CPG5x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0},{"id":"2604116201","title":"Aspire Biopharma files patent application for sublingual alprazolam formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604116201?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:56","pubTimestamp":1768917373,"startTime":"0","endTime":"0","summary":"Aspire Biopharma (ASBP) Holdings announced the filing of a new provisional patent application with the United States Patent and Trademark Office. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-alprazolam-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-files-patent-application-for-sublingual-alprazolam-formulation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2603937660","title":"Aspire Biopharma Holdings Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937660?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:50","pubTimestamp":1768524610,"startTime":"0","endTime":"0","summary":"19:50 EST Aspire Biopharma (ASBP) Holdings Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aspire-biopharma-holdings-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2603616141","title":"Aspire Biopharma Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616141","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616141?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:05","pubTimestamp":1768395930,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a 1-for-40 reverse stock split of its common stock, effective January 16, 2026. The company's shares will begin trading on a split-adjusted basis under the same Nasdaq ticker symbol, ASBP, with a new CUSIP number 738920 206.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8Mt6T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2603658178","title":"Aspire Biopharma Director Surendra Ajjarapu Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658178","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658178?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:31","pubTimestamp":1768339873,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. announced that Surendra Ajjarapu has resigned from his position as Director, effective immediately. The company stated that his departure was not due to any disagreement with the board or management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLFmrw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2601803153","title":"Aspire Biopharma Advances High-Dose Sublingual Aspirin to FDA-Supported Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803153","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803153?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790864,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has announced a successful Type B pre-Investigational New Drug  meeting with the U.S. Food and Drug Administration  regarding its investigational product, acetylsalicylic acid 162 mg sublingual powder , intended for the emergency treatment of suspected acute myocardial infarction. The FDA provided feedback supporting a 505 regulatory filing targeted for the second half of 2026 and indicated that no additional studies are required beyond the currently planned 32-subject clinical trial. Initial evaluations of OTASA have indicated that the product was safe and well-tolerated with no reported adverse events. Results from the planned clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6Yfqgl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASBP","BK4007"],"gpt_icon":0},{"id":"2601890949","title":"Aspire Biopharma Swaps $1.75 Million Debt for Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890949?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:36","pubTimestamp":1767706574,"startTime":"0","endTime":"0","summary":"Aspire Biopharma Holdings Inc. has entered into Exchange Agreements with certain holders of its debt to convert approximately $1.75 million in outstanding debt into shares of the company's common stock. The debt originated from agreements made by the company's predecessor, PowerUp Acquisition Corp., in early 2024. The transaction involves accredited investors and relies on exemptions from registration under the Securities Act. Additionally, the agreements provide that, upon future financings exceeding $3 million, holders may elect to receive a portion of the proceeds in cash to repay outstanding balances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL1bBwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ASBP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aspirebiolabs.com","stockEarnings":[{"period":"1week","weight":-0.028},{"period":"1month","weight":-0.1258},{"period":"3month","weight":-0.6712},{"period":"6month","weight":-0.9396},{"period":"1year","weight":-0.9793},{"period":"ytd","weight":-0.7365}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":-0.11488},{"month":2,"riseRate":0.5,"avgChangeRate":-0.304631},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.201784},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.086181},{"month":5,"riseRate":0.5,"avgChangeRate":0.002353},{"month":6,"riseRate":0.75,"avgChangeRate":-0.091962},{"month":7,"riseRate":0.75,"avgChangeRate":0.106788},{"month":8,"riseRate":0.75,"avgChangeRate":0.136896},{"month":9,"riseRate":0.5,"avgChangeRate":-0.137877},{"month":10,"riseRate":0.75,"avgChangeRate":0.199866},{"month":11,"riseRate":0.5,"avgChangeRate":-0.177747},{"month":12,"riseRate":1,"avgChangeRate":0.063987}],"exchange":"NASDAQ","name":"Aspire Biopharma Holdings Inc.","nameEN":"Aspire Biopharma Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aspire Biopharma Holdings Inc.(ASBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aspire Biopharma Holdings Inc.(ASBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aspire Biopharma Holdings Inc.,ASBP,Aspire Biopharma Holdings Inc.股票,Aspire Biopharma Holdings Inc.股票老虎,Aspire Biopharma Holdings Inc.股票老虎国际,Aspire Biopharma Holdings Inc.行情,Aspire Biopharma Holdings Inc.股票行情,Aspire Biopharma Holdings Inc.股价,Aspire Biopharma Holdings Inc.股市,Aspire Biopharma Holdings Inc.股票价格,Aspire Biopharma Holdings Inc.股票交易,Aspire Biopharma Holdings Inc.股票购买,Aspire Biopharma Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aspire Biopharma Holdings Inc.(ASBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aspire Biopharma Holdings Inc.(ASBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}